Our Semaglutide 1 mg/mL Sublingual Suspension is a meticulously crafted liquid formulation that offers a convenient way to manage certain health conditions. This suspension is specifically designed for sublingual administration, utilizing the innovative SubMagna™ SL HMW base. This advanced vehicle is anhydrous, self-emulsifying, and permeation-enhancing, making it particularly suitable for delivering a wide range of drugs, including those with high molecular weights (HMWs), directly into the systemic circulation via the mucosal tissues under the tongue.

The sublingual route of administration provided by our Semaglutide suspension is particularly advantageous as it bypasses the gastrointestinal tract, thereby avoiding the potential degradation of the active pharmaceutical ingredient (API) and the variable absorption issues associated with oral ingestion. This is especially beneficial for Semaglutide, a medication used in the treatment of type 2 diabetes and obesity, as it ensures more consistent and reliable drug delivery, which is critical for maintaining the therapeutic efficacy of the medication.

Upon application under the tongue, the SubMagna™ SL HMW base interacts with saliva to form an emulsion, which enhances the solubility and dispersibility of Semaglutide. The unique mucoadhesive properties of the base prolong the contact time between the medication and the mucosal tissues, potentially allowing for greater absorption of the API. This feature, combined with the permeation-enhancing effects of the base, facilitates the efficient delivery of Semaglutide into the bloodstream, which may lead to improved glycemic control in patients with type 2 diabetes and support weight management in individuals with obesity.

The anhydrous nature of the SubMagna™ SL HMW base also contributes to the stability of the formulation, offering the potential for extended beyond-use-dates (BUDs), which is an important consideration for both patients and prescribers. The suspension is dispensed in an oral syringe, which allow for precise dosing and ease of administration, making it an ideal option for patients who may have difficulty swallowing tablets or capsules, or for those who require smaller doses.

As compounding pharmacists at Bayview Pharmacy, we are committed to providing high-quality, patient-centered care. We understand the importance of personalized medication solutions and are here to support both patients and prescribers with any questions regarding our Semaglutide 1 mg/mL Sublingual Suspension. Please do not hesitate to reach out to us for further information or guidance on this innovative formulation.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the management of type 2 diabetes mellitus to improve glycemic control in conjunction with diet and exercise. It functions by enhancing insulin secretion, suppressing glucagon secretion, and slowing gastric emptying. When considering drug interactions for semaglutide 1 mg/mL sublingual suspension, it is important to note that the sublingual route bypasses the hepatic first-pass metabolism, which may alter the interaction profile compared to injectable forms.

Concomitant use of semaglutide with insulin or other insulin secretagogues such as sulfonylureas can increase the risk of hypoglycemia. A lower dose of insulin or insulin secretagogues may be required to reduce the risk of hypoglycemia when used in combination with semaglutide. Patients should be advised to monitor their blood glucose levels closely and to be aware of the symptoms of hypoglycemia, which include dizziness, shakiness, sweating, and confusion.

Oral medications that require threshold concentrations for efficacy, such as antibiotics or oral contraceptives, may have reduced effectiveness when administered with semaglutide due to its slowing effect on gastric emptying. Patients may need to consider alternative or additional contraceptive methods to prevent pregnancy and discuss the timing of oral medication dosing with their healthcare provider.

Medications that have a narrow therapeutic index and are sensitive to changes in absorption, such as levothyroxine, may require dose adjustments and close monitoring when used concurrently with semaglutide. Patients should be counseled to maintain a consistent dosing schedule and to watch for signs of altered drug efficacy or adverse effects.

Patients taking medications that can cause hypoglycemia, such as non-selective beta-blockers or alcohol, should be counseled on the increased risk of hypoglycemia and the potential masking of hypoglycemic symptoms when these agents are used with semaglutide. It is advisable to avoid excessive alcohol consumption and to be aware of the signs of hypoglycemia.

It is also important to consider the impact of the SubMagna™ SL HMW base on drug interactions. The base's permeation-enhancing properties may affect the absorption of concomitantly administered sublingual or buccal medications. Healthcare providers should evaluate the potential for altered absorption of other sublingual or buccal medications and adjust dosing or administration times as necessary.

Patients should be advised to inform their healthcare providers of all medications, supplements, and over-the-counter drugs they are taking to ensure a comprehensive review of potential interactions. If any adverse reactions or unexpected effects occur, patients should contact their healthcare provider immediately. For further questions or concerns regarding the semaglutide 1 mg/mL sublingual suspension or its interactions with other medications, please reach out to us at Bayview Pharmacy for professional guidance and support.

\*Note: The beyond-use-date (BUD) will be determined based on the specific formulation and should be strictly adhered to, as per the pharmacy's compounding guidelines and regulatory standards.

The Semaglutide 1 mg/mL Sublingual Suspension is a specialized medication formulated for sublingual administration, which means it is designed to be absorbed under the tongue. This liquid formulation is dispensed via oral syringe, allowing for precise dosing and ease of use, particularly for patients who may have difficulty swallowing pills or require smaller doses. The sublingual route is advantageous as it bypasses the gastrointestinal tract, which can degrade some medications or alter their absorption, leading to variable bioavailability.

Our formulation utilizes SubMagna™ SL HMW base, which is specifically engineered to deliver drugs of varying molecular weights, including high molecular weight (HMW) substances like Semaglutide. This advanced sublingual suspension vehicle is anhydrous, meaning it contains no water, which contributes to its stability and potentially extends its beyond-use date (BUD). The self-emulsifying nature of SubMagna™ SL HMW allows it to form an emulsion upon contact with saliva. This emulsion enhances the solubility and dispersibility of the active pharmaceutical ingredient (API), in this case, Semaglutide.

Furthermore, SubMagna™ SL HMW incorporates permeation enhancers and mucoadhesive properties. These features are critical for promoting the absorption of the medication through the mucosal tissues under the tongue. The mucoadhesive aspect ensures that the medication remains in contact with the sublingual mucosa for an extended period, allowing for more efficient and potentially greater absorption of the API into the bloodstream.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is used in the treatment of type 2 diabetes and, in some cases, chronic weight management. It works by mimicking the effects of the incretin hormones, which are naturally occurring hormones that help regulate blood glucose levels. Semaglutide stimulates insulin secretion and reduces glucagon secretion when blood glucose levels are high. Additionally, it slows gastric emptying and reduces appetite, which can contribute to weight loss in patients with obesity or overweight.

By using the sublingual route with our Semaglutide formulation, patients may experience a more consistent and reliable response to the medication, as it avoids the potential for degradation in the gastrointestinal tract and the first-pass metabolism in the liver, which can occur with orally ingested medications. This could lead to improved glycemic control and better outcomes for patients with type 2 diabetes, as well as support weight management efforts.

If you have any questions or require further information about the Semaglutide 1 mg/mL Sublingual Suspension, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide the support and guidance you need to use this formulation for the treatment of your patients.

While the primary indication for Semaglutide 1 mg/mL Sublingual Suspension is the management of type 2 diabetes mellitus, the unique properties of the SubMagna™ SL HMW base may allow for other potential uses. The ability of this base to deliver high molecular weight (HMW) substances efficiently and its permeation-enhancing characteristics could make it suitable for a range of medications that benefit from sublingual administration. This could include hormones, peptides, or other biological drugs that typically have poor oral bioavailability due to degradation in the gastrointestinal tract or first-pass metabolism in the liver.

Sublingual delivery using the SubMagna™ SL HMW base may also be advantageous for medications that require rapid onset of action, as the sublingual route can offer quicker absorption into the bloodstream compared to oral administration. This could be particularly beneficial for medications used in acute situations, such as certain analgesics, antiemetics, or medications for the treatment of anaphylaxis. Additionally, the mucoadhesive properties of the base prolong contact time with mucosal tissues, which could be useful for drugs that require sustained release for prolonged therapeutic effect.

Furthermore, the anhydrous nature of the SubMagna™ SL HMW base may extend the beyond-use-dates (BUDs) of the compounded medication, which is particularly valuable for drugs that are sensitive to degradation by moisture. This could be an important consideration for drugs that are not frequently used or for those that are compounded in small batches for individual patients. The sublingual suspension form is also ideal for patients who have difficulty swallowing tablets or capsules, such as pediatric, geriatric, or neurologically impaired patients, thereby expanding the potential patient population that could benefit from this formulation.

It is important to note that the use of Semaglutide 1 mg/mL Sublingual Suspension for indications other than type 2 diabetes should be based on clinical evidence and under the guidance of a healthcare professional. If you are a patient or prescriber interested in exploring the potential of this formulation for other uses, or if you have any questions regarding the formulation, please reach out to us at Bayview Pharmacy. Our team of knowledgeable compounding pharmacists is committed to providing you with the information and support you need to make informed decisions about your healthcare or the care of your patients.